Central Nervous System Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Fibromyalgia (FM)
Two statistically significant Phase 3 studies completed, expect to file NDA in 2nd Half 2024
Mid-Phase III
TNX-102 SL Long COVID
Phase II — PREVAIL study complete
Phase II
TNX-102 SL Acute Stress Disorder
Phase II ready
Phase II
TNX-1300 Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation
Mid-Phase II
Rare Disease Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-2900 Prader-Willi Syndrome
Phase II ready – FDA Orphan Drug and Rare Pediatric Disease Designation
Preclinical